Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jan;14(1):55-66.
doi: 10.1038/nrgastro.2016.168. Epub 2016 Dec 7.

Liver - guardian, modifier and target of sepsis

Affiliations
Review

Liver - guardian, modifier and target of sepsis

Pavel Strnad et al. Nat Rev Gastroenterol Hepatol. 2017 Jan.

Abstract

Sepsis and septic shock are characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection. The liver has a central role during sepsis, and is essential to the regulation of immune defence during systemic infections by mechanisms such as bacterial clearance, acute-phase protein or cytokine production and metabolic adaptation to inflammation. However, the liver is also a target for sepsis-related injury, including hypoxic hepatitis due to ischaemia and shock, cholestasis due to altered bile metabolism, hepatocellular injury due to drug toxicity or overwhelming inflammation, as well as distinct pathologies such as secondary sclerosing cholangitis in critically ill patients. Hence, hepatic dysfunction substantially impairs the prognosis of sepsis and serves as a powerful independent predictor of mortality in the intensive care unit. Sepsis is particularly problematic in patients with liver cirrhosis (who experience increased bacterial translocation from the gut and impaired microbial defence) as it can trigger acute-on-chronic liver failure - a syndrome with high short-term mortality. Here, we review the importance of the liver as a guardian, modifier and target of sepsis, the factors that contribute to sepsis in patients with liver cirrhosis and new therapeutic strategies.

PubMed Disclaimer

References

    1. J Clin Invest. 2002 Oct;110(7):1037-44 - PubMed
    1. Cell Metab. 2013 May 7;17(5):657-69 - PubMed
    1. Hepatology. 2007 Nov;46(5):1564-73 - PubMed
    1. Curr Opin Crit Care. 2013 Apr;19(2):128-32 - PubMed
    1. Gut. 1998 Jan;42(1):29-35 - PubMed

Substances